Prostate cancer update: 2005.
OBJECTIVE
The purpose of this review is to highlight the most important developments in the diagnosis, prevention, and management of prostate cancer that have been published in the medical literature in the past year.


RESULTS
Recent research has shown that prostate specific antigen (PSA) velocity can be utilized as a prognostic tool in patients with localized prostate cancer and at the time of serologic relapse. Several novel biomarkers are, however, demonstrating encouraging results in refining or replacing PSA as a screening and prognostic tool. A number of studies have shown that dose and dose intensity of radiation have important ramifications.


CONCLUSIONS
Recent data reported in the past year have significant implications in screening and diagnosis of prostate cancer as well as the management of localized prostate cancer with radiation.
Department of Medicine and UCSF Comprehensive Cancer Center, University of California, San Francisco, CA 94143, USA. ryanc@medicine.ucsf.edu
Charles J
CJ
Ryan
Eric J
EJ
Small
D000230:Adenocarcinoma / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D000728:Androgens; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D004164:Diphosphonates / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008403:Mass Screening; D009376:Neoplasms, Hormone-Dependent / Q000175:diagnosis / Q000628:therapy; D017430:Prostate-Specific Antigen / Q000097:blood; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis / Q000453:epidemiology / Q000628:therapy; D018714:Radiotherapy, Adjuvant; D018570:Risk Assessment
D000728:Androgens; D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D017430:Prostate-Specific Antigen